Franklin Resources Inc. Buys Shares of 36,317 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Franklin Resources Inc. acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 36,317 shares of the biopharmaceutical company's stock, valued at approximately $1,499,000. Franklin Resources Inc. owned 0.06% of Agios Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AGIO. Bank of New York Mellon Corp increased its position in Agios Pharmaceuticals by 13.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company's stock worth $9,622,000 after purchasing an additional 27,193 shares in the last quarter. TD Asset Management Inc raised its stake in shares of Agios Pharmaceuticals by 34.6% in the 2nd quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company's stock valued at $9,076,000 after acquiring an additional 54,054 shares during the period. North Star Asset Management Inc. acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at $216,000. Candriam S.C.A. acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at $13,922,000. Finally, Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth $37,000.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Scotiabank boosted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, December 9th. Leerink Partnrs lowered Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $56.33.

Agios Pharmaceuticals Trading Down 2.8 %

NASDAQ AGIO traded down $0.97 during trading hours on Friday, reaching $33.40. 831,374 shares of the company traded hands, compared to its average volume of 733,408. The stock has a market capitalization of $1.90 billion, a PE ratio of 2.94 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 12 month low of $20.96 and a 12 month high of $62.58. The company has a 50 day moving average of $48.89 and a two-hundred day moving average of $46.18.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.